SCHEDULE 13G

Company

SAB Biotherapeutics, Inc.

Filed

December 4, 2023

Accession Number

0000921895-23-002708

A Schedule 13G is filed when a passive investor acquires more than 5% of a company's shares without intent to influence control. Learn more about SC 13G filings →